Disease states that will be treated will include:

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Inflammatory Arthritis, Systemic Lupus Erythematosus, Dermatomyositis, Vasculitis, Osteoporosis, Immunodeficiency, Gout, Crohn’s Disease, Ulcerative Colitis, Fabry Disease, Iron Deficiency Anemia, Multiple Sclerosis, Guillain-Inflammatory Demyelinating Polyneuropathy (CIPD), Multifocal Motor Neuropathy (MMN), Myasthenia Gravis, Polymytosis, Infectious Disorders,Transplant Recovery, Glomerulonephritis, Asthma, Immunology Primary Antibody Deficiency (PAD), Psoriasis, and any other innovative research therapy after discussion with referring physician.

Therapies will include:

Actemra, antibiotics, antirejection therapies, Benylsta, Boniva, Fabrazyme, Feraheme, injectable therapies, IVIG, IV Steroids, Krystexxa, Nulojix, Orencia, Reclast, Remicade, Rituxan, Simponi, Tysabri, and Xolair.